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Abstract 
The prevalence of gestational diabetes mellitus (GDM)  is increasing as the pregnant popula-
tion becomes older and more obese. Fifteen percent of GDM patients require medical intervention. 
Insulin is still the drug of choice because it has not been implicated as a teratogen in human preg-
nancies. Insulin has its disadvantages such as the need for injections, the risk of hypoglycaemia, 
excessive weight gain and the costs. The use of oral anti hyperglicemic agent (OAHA), traditionally 
contraindicated, now can be considered as an alternative for insulin which can be beneficial in 
developing countries. From four groups of OAHA, sulfonylurea and biguanides can be used during 
pregnancy. Studies and randomized controlled trial (RCT) have been done and most summarized 
that it does not increase any maternal and perinatal morbidity. Most data also show that there 
are also no differences in glycemic control or pregnancy outcomes compared with insulin. There 
are conflicting data shows metformin increase prevalence of preeclampsia patient and perinatal 
morbidity. OAHA usage, although not yet recommended internationally, can be considered in GDM 
patients with uncontrolled blood sugar levels that require medical intervention but can not use in-
sulin. Well conducted, prospective, controlled studies regarding its feasibility in pregnant women 
with diabetes are still needed.
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Penggunaan Obat Hipoglikemik Oral pada Diabetes Gestasional: 
Pro dan Kontra
Abstrak
Prevalensi diabetes mellitus gestasional (DMG) meningkat karena ibu hamil semakin lama 
semakin tua dan gemuk. Sebanyak 15% pasien DMG memerlukan intervensi medis. Insulin 
merupakan obat pilihan karena tidak  teratogen pada kehamilan, namun memiliki kelemahan yaitu 
memerlukan suntikan, risiko hipoglikemia, berat badan berlebihan dan biaya. Obat hipoglikemik 
oral (OHO)  dapat digunakan sebagai pengganti insulin terutama di negara berkembang. Dari 
empat kelompok OHO, sulfonilurea dan biguanid dapat digunakan selama kehamilan. Studi 
dan randomized controlled trial (RCT) menyatakan bahwa OHO tidak meningkatkan morbiditas 
ibu dan bayi. Sebagian besar data juga menunjukkan tidak ada perbedaan dalam kontrol gula 
atau luaran kehamilan dibandingkan dengan insulin. Meskipun demikian terdapat data yang 
menunjukkan peningkatan prevalensi preeklampsia dan morbiditas perinatal pada penggunaan 
metformin. Penggunaan OHO, meskipun belum direkomendasikan secara internasional, dapat 
dipertimbangkan pada pasien DMG dengan kadar gula darah tidak terkontrol yang memerlukan 
intervensi medis tetapi tidak dapat menggunakan insulin. Perlu dilakukan studi prospektif dan 
terkontrol mengenai kelayakan pengunaannya pada ibu hamil dengan diabetes.
Kata Kunci: obat hipoglikemik oral, gestasional, diabetes
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Introduction
Gestational diabetes mellitus (GDM) is associated 
with a higher rate of adverse pregnancy outcomes and 
various neonatal complication.1-3 Its prevalence in the 
United States is 3–5%, which accounts for 90–95% of 
diabetes mellitus (DM) occurring in pregnancy. 2 The 
prevalence is increasing as the pregnant population 
becomes older and more obese. The cornerstone 
of treating a GDM patients is a well-adjusted diet, 
combined with patient education and adapted physical 
exercise routines.4 Approximately 15% of GDM 
patients will not meet glycemic targets with diet alone 
and will require medical intervention. insulin is still the 
drug of choice because it has not been implicated 
as a teratogen in human pregnancies.1, 4-6 Insulin, as 
the drug of choice, has its disadvantages such as 
the need for injections, the risk of hypoglycaemia, 
excessive weight gain and the costs involved.5 The 
use of OAHA that was traditionally contraindicated 
during pregnancy can now be considered as an 
alternative for insulin therapy which can be beneficial 
in developing countries where the proper use of 
insulin is problematic.4-5
Gestational Diabetes Mellitus
GDM is defined as carbohydrate intolerance 
of variable severity with onset or first recognition 
during pregnancy.2-3,6 The overall incidence has 
steadily increased over time, ranging from 2.2% 
in South America to 15% in India. Infants whose 
mothers have DM are at an increased risk for 
future insulin resistance. This association, along 
with the recently increased prevalence of obesity 
and type 2 DM, may lead to a significant rise in 
the occurrence of GDM, with a consequent cycling 
of obesity, insulin resistance, DM, and various 
metabolic complications in future offsprings. There 
is a higher rate of hypertensive complications 
in diabetic pregnancies compared with normal 
pregnancies.7-8 In addition, pre-pregnancy obesity 
and DM also increase the risk of cesarean section 
delivery. Infants born to women with GDM are at 
an increased risk of stillbirth, aberrant fetal growth, 
birth trauma, and various metabolic and electrolyte 
disturbances. Congenital malformations, perinatal 
mortality, macrosomia, neonatal hypoglycemia, 
neonatal hypocalcemia, neonatal polycythemia 
and neonatal respiratory distress is more frequently 
encountered in infants of mothers with DM 
compared with those of non-diabetic mothers.1, 6
GDM is detected by the screening of pregnant 
women,1,3,6 followed, as necessary, by diagnostic 
measures. Two approaches may be followed for 
GDM screening at 24 to 28 weeks: a two-step 
approach that was performed initially by measuring 
plasma or serum glucose 1 hour after a 50 gm oral 
glucose load and perform a diagnostic 100 gm 
OGTT on a separate day in women who exceed the 
chosen threshold on 50 gm screening. The other 
step is one-step approach that perform a diagnostic 
100 gm OGTT in all women to be tested at 24 to 
28 weeks. The 100 gm OGTT should be performed 
in the morning after an overnight fast of at least 8 
hours. The one step approach can be used in place 
with high prevalence of GDM. Some cut off values of 
the OGTT 100 and 75 gram can be seen in Table 1.
     Table 1. Cut-off Values for the OGTT 100 and 75 gm1
Study Fasting 1 hour 2 hours 3 hours
100 gram Carpenter 
and Coustan
95 mg/dl (5.3 mmol/l) 180 mg/dl (10.0 
mmol/l)
155 mg/dl (8.6 
mmol/l)
140 mg/dl (7.8 
mmol/l)
100 gram National 
DM Group
105 mg/dl (5.8 
mmol/l)
190 mg/dl (10.6 
mmol/l)
165 mg/dl (9.2 
mmol/l)
145 mg/dl (8.0 
mmol/l)
75 gram WHO 126 mg/dl (7.0 
mmol/l)
- 140 mg/dl (7.8 
mmol/l)
-
75 gram American 
Diabetes Association
95 mg/dl (5.3 mmol/l) 180 mg/dl (10.0 
mmol/l)
155 mg/dl (8.6 
mmol/l)
-
75 gram Canadian 
Diabetes Association
95 mg/dl (5.3 mmol/l) 190 mg/dl (10.6 
mmol/l)
160 mg/dl (8.9 
mmol/l)
-
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Gestational Diabetes Mellitus Management
The single most important step to achieve 
minimal morbidity and mortality rates in GDM is 
to establish near-normal metabolic control.1 Diet 
and behavioral adjustments are needed. Total 
daily caloric intake that should be allowed per day 
is calculated according to current and ideal body 
weight. Caloric distribution must also be accounted 
because insulin resistance is highest in the morning 
as a result of physiological secretion of cortisol. 
Therefore, carbohydrate-based calories should be 
consumed at later times of the day, and breakfast 
should only be a small meal. Also, exercise 
addresses the issue of insulin resistance, thus may 
be a useful add-on therapy.1-3, 6 If nutritional therapy 
fails to attain the targets (which comprise < 95 
mg% FPG and preprandial glucose and < 120 mg% 
postprandial glucose), insulin therapy is instituted. 
Approximately 15% of GDM patients will not meet 
glycemic targets with diet alone and will require 
medical intervention.1-2 Regular human insulin is 
most frequently prescribed; however, either human 
regular insulin or rapid-acting analogues can 
be used by means of multiple daily injections or 
subcutaneous infusion. 
There are several protocols for insulin 
distribution throughout the day via several 
timed daily injections and according to glycemic 
control.1-2,5,9 One common regimen involves giving 
two-thirds of the total calculated daily insulin dose 
in the morning (fasting, pre-breakfast), made up of 
two parts intermediate-acting to one part regular 
insulin. The remaining one-third of the total daily 
dosage should be divided equally as regular insulin 
(to be given before dinner) and intermediate-acting 
insulin (at bedtime). However, Insulin, as the drug 
of choice, has its disadvantages such as the need 
for injections, the risk of hypoglycaemia, excessive 
weight gain and the costs involved.
Oral Antihyperglycemic Agent:
A new options in Gestational DM treatment
OAHA have traditionally been avoided in women 
with DM in pregnancy because of the potential risks 
of neonatal hypoglycemia, congenital anomalies, 
neonatal hyperbilirubinemia and teratogenicity 
associated with placental transfer to the fetus.10
It have been implicated that first generation 
sulfonylureas are  teratogens in animal studies 
although these early studies failed to show 
conclusively that the compounds themselves and 
not altered maternal metabolism, were the primary 
teratogen. OAHAs are divided into four groups: 
derivatives of sulfonylurea, biguanides, glucosidase 
inhibitors and thiazolidinediones.7, 9
Sulfonylureas cause hypoglycemia by 
stimulating insulin release from pancreatic beta 
cells.9 Their effects are initiated by binding to, 
and blocking, an adenosine triphosphate (ATP)-
sensitive potassium channel. First-generation 
sulfonylureas have been shown to cross the 
placenta. However, there is conflicting evidence 
regarding the newer second generation drugs.5 
With regards to the second-generation sulfonylurea 
agents glibenclamide and glipizide, no teratogenic 
effects were observed in rats and rabbits 
administered large doses of these agents.4 A major 
concern with the use of OAHAs during pregnancy 
is neonatal hypoglycemia which may be severe and 
persist for days. Early studies in rats and mice have 
suggested that tolbutamide and chlorpropamide 
are teratogenic. However, they failed to show 
conclusively that these drugs themselves and not 
altered maternal metabolism, were the primary 
teratogen. A recent in vivo study has shown transfer 
at term but mentions that glyburide appears safe 
to fetus at maternal doses up to 20 mg/d and that 
the glyburide concentration-response relationship 
remains uncertain. Metformin does cross the 
placenta but acts as an insulin sensitizer, not insulin 
secretagogue and is less likely to cause severe 
neonatal hypoglycemia.3,10  Because the adverse 
fetal consequences of maternal DM are believed 
to be related to fetal hyperinsulinaemia, any agent 
that increases fetal insulin production would not be 
recommended for use during pregnancy.3 Recently, 
Hellmuth et al9 followed 68 women treated with 
sulfonylureas during pregnancy, 50 women treated 
with metformin during pregnancy and a control 
group of 42 pregnant women with DM receiving 
insulin. The authors concluded that sulfonylureas 
seem to be well tolerated, but prospective, controlled 
studies are necessary before their widespread use 
can be recommended. 
Less is known about the teratogenic risk 
associated with other classes of OAHAs, such 
as the biguanides, which include metformin and 
phenformin. Metformin is antihyperglycemic 
and not hypoglycemic. It does not cause insulin 
release from the pancreas and does not cause 
hypoglycemia, even in large doses.9,11 The main 
causes of reduced glucose levels during metformin 
therapy appear to be due to an increase in 
insulin action in peripheral tissues and reduced 
hepatic glucose output because of inhibition of 
gluconeogenesis.11 Metformin crosses the placenta, 
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although a partial placental barrier to metformin was 
observed in humans based on fetal concentrations. 
In 1994, Denno (cited from Balani et al7 and 
Hawthorne11) exposed mouse embryos in culture to 
phenformin and metformin and examined them for 
embryotoxicity. Metformin produced no alterations 
in embryonic growth and no major malformations. 
In contrast, phenformin produced dose-dependent 
changes in the incidence of malformations, protein 
content, and embryo lethality. However, metformin 
is not without adverse effects since it produced a 
delay in neural tube closure in 10% of all embryos 
and also reduced yolk sac protein values at two 
different concentrations. There are several recent 
studies of women with polycystic ovary syndrome 
(PCOS) treated with metformin throughout their 
pregnancies.11 Without metformin therapy, women 
with PCOS are frequently infertile and 44% of those 
who become pregnant miscarry in the first trimester 
Acarbose is an oral α-glucosidase inhibitor that 
reduces the rise in blood glucose after meals by 
delaying the digestion of ingested carbohydrates. 
There are lack of human data regarding the use 
of acarbose in pregnancy, hence its use is not 
recommended.4,9
Thiazolidinediones used as an adjunct to 
diet and exercise to improve glycemic control in 
patients with type 2 DM. Currently, there are no 
studies on the use of thiazolidinediones during 
human pregnancy and thus their use for DM during 
pregnancy cannot be recommended.4-5,9
Discussion
Pros
There are various results from studies that 
contradict each other regarding the usage of OAHA 
in GDM. Balani et al7 compared 100 women using 
metformin with 100 women using insulin in GDM 
patients. There was no difference between the 
metformin and insulin groups, comparing gestational 
hypertension, pre-eclampsia, induction of labour 
or rate of caesarean section. Women with GDM 
treated with metformin and with similar baseline 
risk factors for adverse pregnancy outcomes had 
less weight gain and improved neonatal outcomes 
compared with those treated with insulin.7 A meta-
analysis from 6 studies with 1388 subjects by 
Dhulkotia9 shows that there are no differences in 
glycemic control or pregnancy outcomes when 
OAHA were compared with insulin. Metformin 
was not teratogenic and reduced the otherwise 
high likelihood of first-trimester miscarriage in 19 
women with PCOS by ten-fold.  No cases of serious 
neonatal hypoglycemia and a very acceptable rate 
of perinatal morbidity in the offspring of women with 
type 2 DM and GDM treated with metformin over 
a ten-year period. Data regarding the long-term 
implications of metformin use during pregnancy for 
offspring are limited. A cohort of 126 neonates to 
mothers with PCOS who took metformin through 
pregnancy.8 They found no systematic differences 
in growth over the 18 months the infants were 
followed. None of the infants had experienced 
motor developmental delays. No infants developed 
neonatal hypoglycemia and the prematurity rate 
was comparable to community controls
Criteria for the selection of glyburide over 
insulin includes gestational age of 11–33 weeks, 
fasting glucose levels <110 mg/dL on 3-h OGTT, 
and no known sulfa allergy. For women who do not 
meet those criteria, insulin is recommended.12 A 
study to determine the relative impact of maternal 
glycaemic control and modality of maternal anti-
diabetic therapy during early pregnancy on the risk 
of malformations in infants and shows 2 major risk 
factor which are maternal glycohaemoglobin level 
at initial presentation for care and maternal age 
at onset of DM.13 The risk of major malformations 
was unrelated to the mode of antidiabetic therapy 
during early pregnancy.3
Cons
Helmuth et al10 in Denmark with 118 pregnancies 
that treated with OAHA shows that treatment with 
metformin during pregnancy was associated with 
increase prevalence of preeclampsia and high 
perinatal morbidity. 
In vivo studies using mouse embryos shows 
that  approximately 10% of all embryos exposed 
to metformin regardless of dose, exhibited open 
cranial neuropores after 24 hours of culture. A total 
of 20 pregnant women with type 2 DM exposed to 
oral hypoglycemic drugs during embryogenesis 
and 40 pregnant women with type 2 DM who had 
not been exposed. Fifty percent of the infants in 
the exposed group had congenital malformations, 
compared with only 15% of the control group.5 
Conclusion
Insulin is still the drug of choice for GDM 
because it does not cross the placenta and 
provides very good glycemic control in patients. 
OAHA usage, although not yet recommended 
internationally, can be considered in GDM patients 
with uncontrolled blood sugar levels that require 
medical intervention but can not use insulin. 
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Well conducted, prospective, controlled studies 
regarding the feasibility of OAHAs in pregnant 
women with DM are still needed.
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